ROBERT NELSON: Open Payments
NPI 1972696037 · WYOMISSING, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$391,783 in 471 payments from 16 companies in 2025. Trend: 2023 $358,011 · 2024 $408,743 · 2025 $391,783
Speaker / faculty: $272,561Honoraria: $60,125Travel & lodging: $36,875Consulting: $11,490Food & beverage: $10,733
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 116 | $103,930 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 124 | $103,609 |
| Otsuka America Pharmaceutical, Inc. | 90 | $73,899 |
| Axsome Therapeutics, Inc. | 71 | $69,645 |
| Alkermes, Inc. | 43 | $36,366 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,960 |
| Eli Lilly and Company | 3 | $1,900 |
| Neurocrine BioSciences, Inc. | 5 | $134 |
| Vanda Pharmaceuticals Inc. | 6 | $113 |
| Lundbeck LLC | 2 | $50 |
Products named: COBENFY, CAPLYTA, REXULTI, Auvelity, ARISTADA, LYBALVI, REJOYN, INGREZZA.
Industry payments across PA — which companies pay providers there.
